Related Experiment Videos

Proteolytic antibody light chains alter beta-amyloid aggregation and prevent cytotoxicity

Ruitian Liu1, Chad McAllister, Yuri Lyubchenko

  • 1Department of Chemical and Materials Engineering, Arizona State University, Tempe, Arizona 85287, USA.

Biochemistry
|August 4, 2004
PubMed
Summary

Antibody fragments targeting beta-amyloid (Abeta) show therapeutic potential for Alzheimer's disease (AD). One fragment neutralizes Abeta toxicity, while another increases aggregation, highlighting the need for caution with alpha-secretase strategies.

Related Concept Videos